Outlining four considerations for biopharma companies in ensuring that their approach to replacing and filling key leadership positions is more truly aligned with future goals in business delivery and risk management.
Lynn Collins, PhD
Advertisement
Chief Scientist and Co-Head, Assessment, North America, BTS
Articles by Lynn Collins, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Stock Reacts to Recent Board Changes
2
MJH Life Sciences Acquires BPD Healthcare, Expands Reach Among Health Systems and Innovators
3
Bob Mauch: Strengthening the Chain
4
Takeda and Innovent Biologics Announce Strategic Global Partnership
5
